Form 4 for AUPH Aurinia Pharmaceuticals Inc.
Accepted 2024-02-22 00:00:00 ET · period of report 2024-02-20 · accession 0001600620-24-000020 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-22 | 2024-02-20 | AUPH | Donley Matthew Maxwell | EVP, Ops, Strategy | A - Grant | $0.00 | +216.7K | 624.7K | +53% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-20 | A | A | 216,666 | $0.00 | 624,737 | D | — | — | (F1) Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date. (F2) Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 2,500 shares of common stock were acquired on May 31, 2023 and 2,430 shares of common stock were acquired on November 30, 2023. |